Skip to main content

GHRP-6 vs Tesamorelin

Both GHRP-6 and Tesamorelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.

GHRP-6

Evidence B

Growth Hormone Releasing Peptide 6

An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.

View full GHRP-6 profile →

Tesamorelin

Evidence A

Tesamorelin (Egrifta)

An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.

View full Tesamorelin profile →

Side-by-Side

AttributeGHRP-6Tesamorelin
Evidence GradeBA
FDA StatusNot FDA-approved — research compoundFDA-approved for HIV-associated lipodystrophy
Typical Dose100–300 mcg, 1–3 times daily (subcutaneous)2 mg daily (subcutaneous)
Clinics Indexed64178
Categoriesgrowth-hormone, appetitegrowth-hormone, fat-loss

Key reported benefits — GHRP-6

  • GH release
  • Appetite stimulation
  • Cytoprotection

Key reported benefits — Tesamorelin

  • Visceral fat reduction
  • Natural GH stimulation
  • Cognitive benefit
  • Lean mass

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons